The short version of solid-phase synthesis fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-01 and is reviewed periodically as new material appears.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Deka Bike (デカバイク, Deka Baiku): Deka Break's personal police motorcycle-themed Deka Machine that can be ridden by Dekaranger Robo in the Riding Dekaranger Robo (ライディングデカレンジャーロボ, Raidingu Dekarenjā Robo) formation, allowing it to perform the Riding Justice Flasher (ライディングジャスティスフラッシャー, Raidingu Jasutisu Furasshā) attack. Blast Buggy (ブラストバギー, Burasuto Bagī): A combat vehicle–themed Deka Machine from S.P.D.'s Planet Leslie branch that Deka Break pilots during the events of the film Tokusou Sentai Dekaranger The Movie: Full Blast Action.
=== SCD411: Aflibercept Biosimilar === SCD411 is a biosimilar referencing Regeneron and Bayer's Eylea, an anti-VEGF therapy indicated for neovascular age-related macular degeneration (wet AMD) and other retinal diseases. The drug completed global Phase 3 clinical trials in 2022 across 14 countries, involving 576 patients at 132 hospitals. SCD411 received regulatory approvals in Canada (June 2025), Europe (August 2025), South Korea, and Japan (both September 2025), in both vial and pre-filled syringe formats.
=== Decontamination === Treatment of a recently ingested poison may involve gastric decontamination to decrease absorption. Gastric decontamination can involve activated charcoal, gastric lavage, whole bowel irrigation, or nasogastric aspiration. Routine use of emetics (syrup of Ipecac), cathartics or laxatives are no longer recommended. Activated charcoal is the treatment of choice to prevent poison absorption. It is usually administered when the patient is in the emergency room or by a trained emergency healthcare provider such as a Paramedic or EMT. However, charcoal is ineffective against metals such as sodium, potassium, and lithium, and alcohols and glycols; it is also not recommended for ingestion of corrosive chemicals such as acids and alkalis. Cathartics were postulated to decrease absorption by increasing the expulsion of the poison from the gastrointestinal tract. There are two types of cathartics used in poisoned patients; saline cathartics (sodium sulfate, magnesium citrate, magnesium sulfate) and saccharide cathartics (sorbitol). They do not appear to improve patient outcome and are no longer recommended. Emesis (i.e. induced by ipecac) is no longer recommended in poisoning situations, because vomiting is ineffective at removing poisons. Gastric lavage, commonly known as a stomach pump, is the insertion of a tube into the stomach, followed by administration of water or saline down the tube. The liquid is then removed along with the contents of the stomach. Lavage has been used for many years as a common treatment for poisoned patients.
Sources: en.wikipedia.org
=== Musculoskeletal examination of congenital muscular dystrophies === Muscle fibrosis and Joint contractures or fixed deformities are cardinal clinical signs of congenital muscular dystrophies. Muscle fibrosis and shortening eventually lead to joint contractures or fixed deformities. They are important to the diagnosis of CMD. However, some patients initially present with joint laxity. Joint deformities can occur in the extremities and spine. Severe deformities can result in joint dislocation and walking difficulties or gait abnormalities. However, the specific pattern of muscle involvement in each of the CMD subtypes is not fully elucidated. A recent review identified CMD subtype-specific clinical patterns of muscle and Joint involvement which could be of help to the differential diagnosis of CMD subtypes. This was especially true for Merosin-deficient congenital muscular dystrophy (MDC1A) or LAMA2-related CMD subtype. Nonetheless, these muscle and Joint patterns of involvement have to be correlated with other clinical signs, neuro-imaging reports, muscle biopsy immune-staining and molecular or genetic analysis results, whenever available. This comprehensive approach is critical for the correct and timely diagnosis of CMDs.
Gliomas (glial cell tumors) Oligoastrocytoma, Choroid plexus papilloma, Ependymoma, Astrocytoma (Pilocytic astrocytoma, Glioblastoma multiforme), Dysembryoplastic neuroepithelial tumour, Oligodendroglioma, Medulloblastoma, Primitive neuroectodermal tumor Neuroepitheliomatous tumors Ganglioneuroma, Neuroblastoma, Atypical teratoid rhabdoid tumor, Retinoblastoma, Esthesioneuroblastoma Nerve sheath tumors Neurofibroma (Neurofibrosarcoma, Neurofibromatosis), Schwannoma, Neurinoma, Acoustic neuroma, Neuroma
=== Health care === In 2019, Pritzker approved a tax on private insurance to help fund the state's Medicaid program. In August of that year, he signed legislation to eliminate the state's backlog of Medicaid applications, which as of March 15, 2019, included 112,000 that remained unprocessed past the federal 45-day limit. According to data from the Illinois Department of Human Services, the backlog was eliminated as of June 2020. In August 2023, under provisions of Illinois House Bill 2189 (the Access to Afford Insulin Act), Pritzker signed legislation capping insurance holders' out-of-pocket price of insulin at $35 for a 30-day supply. In July 2024, Pritzker signed bills allowing Illinois to spend $10 million to purchase medical debt from creditors, known as the Medical Debt Relief Pilot Program, under the Illinois Department of Healthcare and Family Services. The program was created to eliminate nearly $1 billion in medical debt for 340,000 low-income state residents. In February 2025, Pritzker announced that approximately 270,000 Illinoisans' medical debt, totaling $345 million, had been erased under the program. On April 22, 2025, United States Secretary of Health and Human Services Robert F. Kennedy Jr. announced a plan to use government data to help determine the causes of autism. In response, Pritzker signed an executive order that made Illinois the first state to block the federal government from collecting personal health data related to autism. In 2025, Pritzker signed Illinois House Bill 1697, the Prescription Drug Affordability Act.
Sources: en.wikipedia.org
DALDA (H-Tyr-D-Arg-Phe-Lys-NH2) is a synthetic peptide which acts as a potent and highly selective agonist of the mu opioid receptor. It is a metabolically stable analogue of dermorphin, a naturally occurring opioid peptide secreted by some species of South American frogs. DALDA is unable to cross the blood-brain barrier, making it highly peripherally selective, but it has been researched for the treatment of colitis and neuropathic pain, where peripheral opioid agonism is able to produce analgesic effects in the absence of central opioid receptor activation. Some derivatives of DALDA such as [Dmt1]DALDA (where the tyrosine residue has been replaced with 2,6-dimethyltyrosine) or more complexly modified derivatives such as KGOP01, do however cross the blood-brain barrier and produce typical opioid effects.
About 86% of molybdenum produced is used in metallurgy, with the rest used in chemical applications. The estimated global use is structural steel 35%, stainless steel 25%, chemicals 14%, tool & high-speed steels 9%, cast iron 6%, molybdenum elemental metal 6%, and superalloys 5%. Molybdenum can withstand extreme temperatures without significantly expanding or softening, making it useful in environments of intense heat, including military armor, aircraft parts, electrical contacts, industrial motors, and supports for filaments in light bulbs. Most high-strength steel alloys (for example, 41xx steels) contain 0.25% to 8% molybdenum. Even in these small portions, more than 43,000 tonnes of molybdenum are used each year in stainless steels, tool steels, cast irons, and high-temperature superalloys. Molybdenum is also used in steel alloys for its high corrosion resistance and weldability. Molybdenum contributes corrosion resistance to type-300 stainless steels (specifically type-316) and especially so in the so-called superaustenitic stainless steels (such as alloy AL-6XN, 254SMO and 1925hMo). Molybdenum increases lattice strain, thus increasing the energy required to dissolve iron atoms from the surface. Molybdenum is also used to enhance the corrosion resistance of ferritic (for example grade 444) and martensitic (for example 1.4122 and 1.4418) stainless steels. Because of its lower density and more stable price, molybdenum is sometimes used in place of tungsten.
=== 5 December === Explosions were reported at two Russian airbases: the one at Engels-2 reportedly damaged two Tu-95s; the other at the Dyagilevo military airbase near Ryazan, destroyed a fuel truck and killed three, injuring five. The Russian Ministry of Defence stated Ukraine attempted to strike Russia's long-range aviation bombers with Soviet-made jet drones, and that the drones were subsequently shot down at low altitude when approaching the air bases. The attack involved the use of Tu-141 drones that were taken out of storage and appeared to have been fitted with improvised explosives. While no significant damage or burn marks were visible on satellite images of Engels-2, at least one Tu-22M3 bomber was visually confirmed to be slightly damaged at Dyagilevo. Following the attacks, Russia launched a renewed wave of missile strikes against Ukraine, consisting of about 70 cruise missiles. Ukraine claimed 60 missiles were shot down, Russia claimed 17 targets were hit on the ground. As a result, a missile fell into the territory of Moldova, near the city of Briceni.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
Dry lyophilized powder tolerates short ambient exposure during handling and shipping. Long-term room-temperature storage is not recommended because moisture uptake and slow degradation can occur over months. Storage at minus twenty degrees Celsius is the common practice for extended periods.